ERBB2 and breast carcinoma: Given the different mechanisms by which α-TEA and trastuzumab mediate tumor cell death [3,26-29], we hypothesized that combining α-TEA with HER2/neu-specific antibody will result in enhanced anti-tumor activity against HER2/neu-expressing breast cancer.